Phase 3 Ovarian Cancer Trial, Recruiting NCT07472140 Sponsor: N.N. Alexandrov National Cancer Centre Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT07472140
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old.
  • You have been diagnosed through a tissue sample (biopsy) with a specific type of high-grade ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (a cancer starting in the lining of the abdomen).
  • You are in generally good health and able to carry out daily activities with little or no limitation (confirm with trial site).
  • You are able to undergo a keyhole exploratory procedure or surgery to remove as much of the cancer as possible.
  • Your cancer has a specific genetic characteristic called homologous recombination deficiency, or HRD (confirm with trial site).
  • You have no medical reasons preventing you from receiving chemotherapy or a drug called bevacizumab.
  • You are willing and able to sign a consent form to take part in the study.

Who may not be able to join:

  • You currently have another active cancer that has spread into surrounding tissues.
  • You are pregnant or currently breastfeeding.
  • Your cancer has continued to grow or spread while already receiving treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 80291985715

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
N.N. Alexandrov National Cancer Centre
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
30 June 2033

Where this trial is recruiting

Belarus

Primary endpoints

Disease-free survival; The frequency of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov